another recent paper using this approach
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0397-z
The hypothesis is that engineered MSCs which injected intravenously into the tumor-bearing mice would specifically migrate to tumor site and secrete Tandab (CD3/CD19) which recruits T cells to exhibit a potent antitumor immunity in combination with an IDO pathway inhibitor D-1MT. And results presented here support the feasibility of this strategy.
We have demonstrated in this study that human UC-MSCs can be acted as cell-based delivery vehicles for the treatment of B cell lymphoma. Tandab (CD3/CD19) secreted from UC-MSCs effectively redirected T cells to inhibit the growth of Raji lymphoma in mouse models in combination with D-1MT. Our findings indicate that the use of UC-MSCs as vehicles for engineered-antibodies combined with immunoregulatory agents represents a potential clinical application of gene therapy for cancers.
- Forums
- Charts
- MSCs and Breast Canvcer
another recent paper using this approach...
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $44.90M |
Open | High | Low | Value | Volume |
25.0¢ | 26.5¢ | 24.5¢ | $29.84K | 119.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 28000 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.5¢ | 73392 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 28000 | 0.245 |
1 | 2000 | 0.240 |
2 | 15173 | 0.230 |
1 | 500 | 0.200 |
1 | 50000 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.265 | 73392 | 3 |
0.270 | 30000 | 1 |
0.290 | 4125 | 2 |
0.295 | 183892 | 1 |
0.345 | 6124 | 1 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online